Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

Sansai, K.; Takuathung, Mingkwan Na; Khatsri, Rapheephorn; Teekachunhatean, Supanimit; Hanprasertpong, Nutthiya; Koonrungsesomboon, Nut

doi:10.1007/s00198-020-05476-z

Cited by 44 publications

(28 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some of that enthusiasm faded as subsequently published research produced equivocal findings (Balk et al 2005). Nevertheless, research into the benefits of soy and isoflavoneswith results often supportive of efficacycontinue to be published at an impressive rate (Man et al 2021;Sansai et al 2020;Cui et al 2020;). However, concerns about the safety of isoflavones have led to these soybean constituents, and as a result, to soyfoods, becoming controversial.…”

Section: Discussionmentioning

confidence: 99%

Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data

Messina

Mejía

Cassidy

et al. 2021

Critical Reviews in Food Science and Nutrition

View full text Add to dashboard Cite

Soybeans are a rich source of isoflavones, which are classified as phytoestrogens. Despite numerous proposed benefits, isoflavones are often classified as endocrine disruptors, based primarily on animal studies. However, there are ample human data regarding the health effects of isoflavones. We conducted a technical review, systematically searching Medline, EMBASE, and the Cochrane Library (from inception through January 2021). We included clinical studies, observational studies, and systematic reviews and meta-analyses (SRMA) that examined the relationship between soy and/or isoflavone intake and endocrine-related endpoints. 417 reports (229 observational studies, 157 clinical studies and 32 SRMAs) met our eligibility criteria. The available evidence indicates that isoflavone intake does not adversely affect thyroid function. Adverse effects are also not seen on breast or endometrial tissue or estrogen levels in women, or testosterone or estrogen levels, or sperm or semen parameters in men. Although menstrual cycle length may be slightly increased, ovulation is not prevented. Limited insight could be gained about possible impacts of in utero isoflavone exposure, but the existing data are reassuring. Adverse effects of isoflavone intake were not identified in children, but limited research has been conducted. After extensive review, the evidence does not support classifying isoflavones as endocrine disruptors.

show abstract

Section: Discussionmentioning

confidence: 99%

Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data

Messina

Mejía

Cassidy

et al. 2021

Critical Reviews in Food Science and Nutrition

View full text Add to dashboard Cite

show abstract

“…Meta-analysis of 63 RCTs found that genistein (54 mg/day) and ipriflavone (600 mg/day) in particular, have beneficial effects on BMD outcomes and are safe in postmenopausal women. Therefore, they may be considered as a complementary or alternative therapy and the prophylaxis of menopause-related osteoporosis [ 15 ]. Another meta-analysis of 26 randomized controlled trials (2652 oestrogen-deficient women) found that isoflavones attenuated moderately menopause-associated bone loss in the lumbar spine, femoral neck and distal radius [ 71 ].…”

Section: Phytoestrogensmentioning

confidence: 99%

“…Alfalfa, as other legumes, is a known source of phytoestrogens, including spinasterol, coumestrol, coumestan, and ipriflavone. As mentioned above, the meta-analysis of 63 controlled trials investigating 6427 postmenopausal women revealed that ipriflavone (600 mg/day) is a promising molecule for the prevention and treatment of postmenopausal osteoporosis [ 15 ]. Ipriflavone has been reported to induce osteoblast proliferation and prevent menopause-related bone loss.…”

Section: Phytoestrogensmentioning

confidence: 99%

Botanicals in Postmenopausal Osteoporosis

2021

View full text Add to dashboard Cite

Osteoporosis is a systemic bone disease characterized by reduced bone mass and the deterioration of bone microarchitecture leading to bone fragility and an increased risk of fractures. Conventional anti-osteoporotic pharmaceutics are effective in the treatment and prophylaxis of osteoporosis, however they are associated with various side effects that push many women into seeking botanicals as an alternative therapy. Traditional folk medicine is a rich source of bioactive compounds waiting for discovery and investigation that might be used in those patients, and therefore botanicals have recently received increasing attention. The aim of this review of literature is to present the comprehensive information about plant-derived compounds that might be used to maintain bone health in perimenopausal and postmenopausal females.

show abstract

“…También se les ha conferido efectos benéficos cardiovasculares y óseos [41][42][43] . Al respecto existen datos positivos y neutrales en ganancia de masa ósea; por ejemplo, está descrito que la administración de fitoestrógenos puede inhibir la diferenciación y activación de los osteoclastos y de otras moléculas que participan en el equilibrio del remodelado óseo, pero estos efectos no se han podido reproducir en todos los casos 44 . El uso de fitoestrógenos se ha asociado con incremento en la concentración de lipoproteínas de alta densidad, que provee protección cardiovascular.…”

Section: Fitoestrógenosunclassified

Hormonas bioidénticas y fitoestrógenos

López-Juárez¹,

López-Tarabay²,

Pérez-Galván³

et al. 2021

RME

View full text Add to dashboard Cite

In the last 20 years, the prescription of bioidentical hormones has increased exponentially, specifically in the treatment to alleviate symptoms of menopause. The increase in the use of these compounds responds to incomplete, incorrect or unsustainable information regarding the safety or efficacy that they claim as "natural" and "innocuous", alluding to their manufacture and "personalized" adjustment, however, none of the manufacturing or the control processes are standardized so the quality of these products are questionable. On the other hand, phytoestrogens are mostly classified as supplements, which are not subject to specific regulation, and the response to their use varies, depending on the existence of the appropriate intestinal microbiota for metabolize them into active compound. This document will review evidence related to the use of these formulations.

show abstract

Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

Cited by 44 publications

References 59 publications

Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data

Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data

Botanicals in Postmenopausal Osteoporosis

Hormonas bioidénticas y fitoestrógenos

Contact Info

Product

Resources

About